Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Peter Zdziarski: Will Glanzmann Thrombasthenia Patients Be Formally Recognized as Benefiting from SevenFACT?
Peter Zdziarski/LinkedIn
Apr 15, 2026, 15:33

Peter Zdziarski: Will Glanzmann Thrombasthenia Patients Be Formally Recognized as Benefiting from SevenFACT?

Peter Zdziarski, Founder and Marketing Director of Glanzmann Thrombasthenia Advocacy Network, shared a post on LinkedIn:

“We’re seeing something important in the Glanzmann Thrombasthenia (GT) community.

More patients are using SevenFACT to manage bleeds, with consistently strong feedback.

Given the rarity of this condition and the limited, often unpredictable treatment options, we are always looking for more.

It’s also important to recognize how GT patients approach treatment.

Many prefer on-demand therapies used at the time of a bleed rather than methods requiring ongoing weekly dosing. Flexibility and real-time control are critical.

As real-world use continues to grow, it raises a simple question for HEMA Biologics:

Will Glanzmann Thrombasthenia patients be more formally recognized as a group that can benefit from SevenFACT?

Recognition drives awareness.

Awareness drives access.

And access is everything for rare disease communities.

There’s clear momentum here.

It’s worth paying attention to!”

More posts featuring Peter Zdziarski on Hemostasis Today.

 

 

Glanzmann thrombasthenia Glanzmann's Research Foundation Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine NORD Sevenfact
NewsFeed